Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
No funding
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Cancer Institute (NCI) | NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
This clinical trial studies positron emission tomography (PET) imaging utilizing 18F-FSPG [(S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid], a glutamic acid derivative, to image patients with ovarian cancer before undergoing surgery or transplant. Diagnostic procedures, such as 18F-FSPG PET, may help find and diagnose ovarian cancer and find out how far the disease has spread.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Experimental | Experimental | Patients receive (S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG) PET scans. Patients undergo PET imaging scans during 0-45 minutes, 60-75 minutes, and 105-120 minutes after injection and within 4 weeks prior to surgery (Cohort A) or within 4 weeks of SOC imaging at diagnosis and prior to subsequent treatment (Cohort B). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| (S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG) | Drug | Given by IV |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Lesion (S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG) PET standard uptake values | Up to 2 years | |
| Number of lesions detected by(S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG) PET | Up to 2 years | |
| Number of lesions detected by (S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG) PET imaging before and after neoadjuvant chemotherapy treatment | Up to 2 years |
| Measure | Description | Time Frame |
|---|---|---|
| Immunohistochemistry evaluation of xC- and CD 44 of resected malignant ovarian cancer with a measurement of strength of staining from 0-3. | All imaging data (SUV) will be correlated to definitive, ex vivo diagnostic pathology and immunoreactivity (xC-, CD44), which will be carried out for every patient with resected tissue. and, when IHC scoring will be in terms of strength of immunostaining (scored on an ordinal scale of 0 3). This treatment of lesion-based sensitivity and specificity has not been previously described in the ovarian cancer literature. |
Not provided
Inclusion Criteria:
Have a presumed diagnosis of advanced stage epithelial ovarian, fallopian tube, or peritoneal.
Pelvic mass and/or omental caking with Ca-125:CEA ratio 25:1.
Adequate organ function:
Have undergone or have agreed to undergo standard of care CT of the chest, abdomen, and pelvis. 18F-FSPG PET imaging will be performed as investigational studies.
No prior treatment for ovarian cancer
have undergone or agree to undergo standard of care imaging for ovarian cancer with CT chest, abdomen, and pelvis.
Exclusion Criteria:
Have non-invasive or non-epithelial ovarian cancer on pathological confirmation.
Pregnant and breastfeeding
Poorly controlled diabetes mellitus (fasting blood glucose level > 200 mg/dL).
Other poorly controlled medical conditions that in the opinion of the surgeon, make them not a candidate for primary cytoreductive surgery.
CT of chest, abdomen, pelvis demonstrates:
Any disease in the thoracic cavity > 1 cm.
Any suprarenal lymphadenopathy > 1 cm.
Liver metastases > 1 cm.
Disease in the porta hepatis or gallbladder fossa > 1 cm.
Pleural effusion > 50% volume of the chest cavity on chest x-ray.
Omental extension to the stomach, spleen, or lesser sac.
Decline procedures that might be necessary for optimal primary cytoreduction (i.e. colostomy or splenectomy).
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Marta Crispens, MD | Vanderbilt University Medical Center | Principal Investigator |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Positron Emission Tomography |
| Procedure |
Undergo scan |
|
| Laboratory Biomarker Analysis | Other | Laboratory Biomarker Analysis |
|
| Up to 2 years |
| Proportion of patients whose surgical resection by novel imaging classification changed following validation by histological confirmation | Up to 2 years |
| Proportion of patients whose response to chemotherapy changed by Response Evaluation Criteria in Solid Tumors criteria | Up to 2 years |
| Conditional predictive models of imaging performance and agreement | We will test that lesion 18F-FSPG PET SUV's are significantly greater than background (normal liver tissue) by tissue assessment of number of lesions noted in each arm and after treatment. | Up to 2 years |
| ID | Term |
|---|---|
| D005185 | Fallopian Tube Neoplasms |
| D010051 | Ovarian Neoplasms |
| ID | Term |
|---|---|
| D005833 | Genital Neoplasms, Female |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D005184 | Fallopian Tube Diseases |
| D000291 | Adnexal Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D000091662 | Genital Diseases |
| D004701 | Endocrine Gland Neoplasms |
| D010049 | Ovarian Diseases |
| D004700 | Endocrine System Diseases |
| D006058 | Gonadal Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| C000623325 | 4-(3-fluoropropyl)glutamic acid |
| D009682 | Magnetic Resonance Spectroscopy |
| ID | Term |
|---|---|
| D013057 | Spectrum Analysis |
| D002623 | Chemistry Techniques, Analytical |
| D008919 | Investigative Techniques |
Not provided
Not provided